.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin resulted in improved progression-free as well as overall survival, resulting in FDA approval as well as a brand-new therapy option for individuals.